课题基金 / 基金详情

BUDESONIDE CONTROLLED RELEASE CAPSULES AS MAINTENANCE IN CROHN'S DISEASE

BUDESONIDE CONTROLLED RELEASE CAPSULES AS MAINTENANCE IN CROHN'S DISEASE
布地奈德控释胶囊用于克罗恩病的维持治疗
批准号：
6121129
负责人：
ALAN L. BUCHMAN
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6121129
关键词：
Crohn's disease clinical research dosage forms gastrointestinal agents gastrointestinal disorder chemotherapy glucocorticoids human subject human therapy evaluation remission /regression

项目摘要

项目成果

ALAN L. BUCHMAN的其他基金

相似基金

相关文献

中文摘要
翻译
这项研究是为参与过布地奈德治疗活动性克罗恩病研究的患者设计的。 它将确定那些已经达到急性疾病缓解的患者在服用布地奈德时是否会比服用安慰剂时达到更长的缓解。急性试验完成后，受试者将立即随机接受布地奈德胶囊6 mg/d或安慰剂，治疗期为52周。
英文摘要
This study is designed for patients who participated in a previous study of the drug budesonide in active Crohn's disease. It will determine if patients who have achieved remission of their acute disease will achieve a longer remission when taking budesonide than when taking placebo. Immediately upon completion of the acute trial, subjects will be randomized to receive budesonide capsules 6 mg daily or placebo for a treatment period of 52 weeks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF HEPATIC STEATOSIS ASSOCIATED WITH TOTAL PARENTAL NUTRITION
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
USE OF CLONIDINE TO REDUCE DIARRHEA LOSSES IN PATIENTS WITH PROXIMAL JEJUNOSTOMY
SAFETY AND EFFICACY OF ISIS 2302 IN STEROID DEPENDENT CROHN'S DISEASE
海外基金